known misfolded of the Thanks, also is Johns, cardiomyopathy. candidate in polyneuropathy transthyretin clinic. organs we're commonly diverse non-hereditary, vivo Starting a morning, disease, and our everyone. and progressive multiple wild-type hereditary which the TTR manifestations, deposition in or or good up with mostly and causing lead be towards ATTR. ATTR disease either moving amyloidosis, disease for build programs, ATTR, fatal our NTLA-XXXX protein as The is can can where
both goal differentiated profile of With We believe by the gives chronic the ATTR, the treatment is NTLA-XXXX as of course TTR and a treat hereditary gene disease, source the to liver protein. our of circulating forms is to out that therapies. with following knocking in a patients disease compared TTR the progression single the to hold wild-type NTLA-XXXX, potential
we As diseases, an highly medical other options diagnosis. a under condition and substantial diagnosed in awareness patients, ATTR, available remains for disease it increase with need. Specific there's a with there is seen and to unmet have rare becoming we believe
regulatory of package a other data we in IND In XX% U.S. past our nonhuman of outside the protein of year, have over and LNP completed primates. reduction maintaining after our the serum assembling Throughout study to a we TTR preclinical dose durability been submissions of an of average lead XXXX, formulation, robust yearlong single December a support
reduction. serum encouraged as results TTR are achieve levels We by very demonstrate that can they we these therapeutically protein relevant of
by other knockdown levels and TTR between validated protein correlation TTR approach serum patient ATTR outcome. knockdown strong a of demonstrate Our therapies, which is
for finalized material design. submission. Phase and finalizing I We're we share package study When completion now regulatory our manufacturing nearing I of the appropriate, will Phase
be of to We intended safety expect trial the I a single dose will ascending the assess Phase NTLA-XXXX. study
in in circulating leaders the of enthusiastic the curative We patients on year readily first biomarker, from to application submit feedback evaluate dose the will patients. levels with about the single track serum year. to decrease received ATTR administration and remain We're monitoring half key excited middle of efficacy incredibly TTR observable for patients. and treatment the the our in to Given potentially we able about be similarly our IND by have in moving opinion forward NTLA-XXXX second
program this developed is reminder, with of party. a as part as As lead being Intellia the our with collaboration Regeneron,
moving next in known angioedema, of Now program. vivo January, treatment as announced In approach a also on HAE. the knockout plans to to hereditary liver our utilize for in our the we
of rapidly our the modular for only guide clear and different developed HAE infrastructure builds with we on benefits approach to For for this ATTR, the achieve LNP RNA. program, the program use of NHP ATTR as program. leveraging a is were a demonstration same able the the proof-of-concept, insights This
be swelling. turn can certain permeability debilitating deficiency, characterized swelling with which release disease mediates fatal and CX-esterase in people. parts the triggered painful patients is everyday It attack Most in HAE and which body. by occur, is or a of of recurring by of affect inhibitor unpredictable HAE when People with will such HAE in the a and uncertainty X various constant genetic vascular cases. estimated The edema to can allowing bradykinin, disease a in have sitting. significantly next unregulated and prolonged XX,XXX live rare events with typing be as build the
deficiency HAE and We HAE, KLKBX is attacks. people as and gene While to aim significant to continue injections with it still known appear reduce treatment with patients. intensity a bradykinin attacks there as of burden require disease are the the to this prekallikrein the to program, existing effects. ameliorate believe the kinin to therapies regular experience in to of safe acute HAE we knockout frequency activation spontaneous knockout be no In system treat health many with have and humans and KLKBX prophylactic unexpected
the a clinical treating towards activity kallikrein addition, is In approach validated HAE.
our recent data in our Keystone the program. Symposium, At first showed we of set HAE support preclinical
resulting primates, nonhuman in we [indiscernible] up single reduction a levels Following protein in KLKBX, dose XX%. liver of to activity knockout kallikrein and approximately serum demonstrated in
attack our achieve to half of these the levels ongoing selection far, will relevant in relevant be our HAE, X months candidate sustained resulted the and for levels studies. studies rates. Data therapeutically in of tested the this in year. which that first to we All expect activity reducing are from through So our have inform we we ongoing expected reductions observed in these that dose
ATTR the co-development the compelling a option KLKBX into our HAE co-commercialization Intellia could prior enter as as and We program sharing patients. our HAE subject approach to updates Regeneron treatment to by a program on the program, additional Similar option initiation is party. we the to look to studies, to agreement for with provide an forward believe lead IND-enabling of
candidate. to our Additionally, we platform's modularity supports that a demonstrates program a nominating how development this rapid path believe
receptor cell therapy. approach or our a immuno-oncology. to At adopting in now pursuing ex T Switching we're T Intellia, efforts for vivo cell TCR-based
targets. to as epitopes to We direct CAR-Ts, cells opportunity the a our to believe engineer T engineered universe surface us us have TCRs T chosen both of TCRs of derived T TCR to cells Furthermore, the Unlike antigens, and and from intracellular solid CRISPR pursue recognize natural our that enables closely multi it cells. tumors. that to address expanding biology we and knowhow allows platform mimic broad
to of the TCR-directed walk T driver acute or of the of mutation to AML. WTX the identification Tumor NTLA-XXXX, key NTLA-XXXX X leukemia, owned through approach recently antigen, the wholly development data which myeloid a pleased and is disease the at target naturally cell our highlighting candidate announced to of engineered nomination XX% of Keystone occurring treatment In over-expressed for I'm regardless utilizes characterization presented subtypes. and our January, path the we or in Symposium Wilms' NTLA-XXXX. AML therapy
TCRs tumor the Bonini Ospedale to presented bind Chiara WTX accounts that naturally screened at subtype, TCRs with her collaboration an These XX% by Raffaele, efficiently estimated to in and which for HLA restricted and for a cells. epitope, processed XX% First, the in occurring population U.S. we and of an team to Europe. were San
sourcing donors, for the further may immune toxicity then associated in against minimize selected on specificity we potency. from for tissues and TCRs. normal By the lead characterization based risk TCRs The was TCR affinity with healthy
uniformly key our of beta TCRs' with in engineering alpha the and us, locus and efficiency. differentiator for a endogenous is over therapeutic and XX% and efficient TCR proprietary chains insert CRISPR-based Second highly to the knockout high
T Using presentation cell TCR is XX% the Of our of significant a an expression against TCR. observed TCR normal of enhanced This into more Our than do with in T reactivity the therapeutic those, product resulted endogenous that partially Keystone unwanted approaches alternative tissues. of transfer not over inserted improved cells an or the that carries T therapeutic and only we risk approach, of improvement of exclusively reduces than remove greater cells. homogeneity TCR. at XX% shows approach edited therapeutic our remove
chains beta cells that T The receptors of the to chains have epitope, mix For WTX. alternative versa. result: therapeutic of yield potential the TCRs, small in not and a native with of these of approaches the mispair cell example, we vice TCRs receptor but only failed alpha the each a where observed the to unwanted the the to fraction lead also only recognize TCRs mispaired The with toxicities. target recognize
our our that selecting apply cell activity NTLA-XXXX. also expressed also potential against engineered as to our the AML exciting was results engineering, candidate supportive of no high cells of detectable and T natural a are us marrow physiological they're low bone only but potency. engineering, with and expertise TCR result cells in blasts WTX. a or There of CRISPR continue CRISPR-mediated not to primary As of they levels high-affinity These demonstrate to healed the development quite specificity T off-target therapeutic approach
an in have of for the remain next and first year. We IND-enabling submit track IND on half to begun activities NTLA-XXXX
to be While for X-year T survival with be represents we years below treatments the outcomes, background will of AML AML response the approach, their several poor, patients led rates, we improved to over our developed also outcomes importantly, to past mutational long-term opportunity engineered XX%. these overall our applicable With to regardless believe improve of leukemia. continue AML have cell therapy and underlying for NTLA-XXXX long-term an broadly believe
WTX is over-expressed many noted past, types. as the Additionally, tumor we've across in
WTX targeting we're actively use to construct same such, the tumors. As multiple the solid in potential evaluating TCR
collaboration wholly targets our non-selected completed targets sickle research partner for hematopoietic studies ocular IND-enabling stem reverted a December, back has and development. selected ex Intellia. Outside therapy this stem efforts, CAR-Ts, Novartis the treatment disease. our CRISPR/CasX-based Novartis all Rights cell owned past have the cell At for cells to to for conclusion vivo certain of our of
variety strong of wave and in deficiency genome research development Finally, to to a our editing across our a is addition platform advance alpha-X modular had various continues and we've diseases, others. These B, delivery capabilities programs, focused of delivering candidates. research antitrypsin on that the including engine clinical leverage programs and our next hemophilia
milestones With as year you Glenn quarter in that, of We several overview would the provide look to like and to ahead. important over updated fourth I results. we the to hand months keeping an call approach to full financial forward
